|
|
| Line 1: |
Line 1: |
| {{drugbox
| | #REDIRECT [[Alprostadil]] |
| | IUPAC_name = 7-[3-hydroxy-2-(3-hydroxyoct-1-enyl)- 5-oxo-cyclopentyl] heptanoic acid
| |
| | image =
| |
| | CAS_number = 745-65-3
| |
| | ATC_prefix = C01
| |
| | ATC_suffix = EA01
| |
| | ATC_supplemental = {{ATC|G04|BE01}}
| |
| | PubChem = 149351
| |
| | DrugBank = APRD00785
| |
| | C=20 | H=34 | O=5
| |
| | molecular_weight = 354.481 g/mol
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category =
| |
| | legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| |
| | legal_UK = <!-- GSL / P / POM / CD -->
| |
| | legal_US = <!-- OTC / Rx-only -->
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
| {{SI}}
| |
| {{CMG}}
| |
| __NOTOC__
| |
| | |
| | |
| ==Overview==
| |
| | |
| '''Alprostadil''' is the pharmaceutical name for [[prostaglandin]] E<sub>1</sub>. It is used as a drug in the treatment of [[erectile dysfunction]] and has [[vasodilatory]] properties.<ref name=dorlands>{{Dorlands|a_26|12123006}}</ref>
| |
| | |
| ==Sexual dysfunction==
| |
| Aprostidil is sold in the United States under the brand name Muse.<ref>[http://www.drugdigest.org/DD/DVH/Uses/0,3915,550749|Muse,00.html Muse].</ref> It is also sold as Caverject and Edex.
| |
| | |
| Muse delivers alprostadil as a penile [[suppository]], inserted into the urethra, at least ten minutes before the erection will be needed. Caverject and Edex are similarly fast-acting, but are actually injected directly into the [[corpus cavernosum penis|corpus cavernosum of the penis]].
| |
| | |
| This drug is reputed to work for erectile dysfunction for 30 to 60 minutes.
| |
| | |
| This drug, following on the coattails of [[Viagra]], has failed to achieve comparable above-ground market share in the United States, perhaps in part because of the invasive means of delivery.
| |
| | |
| NexMed is developing transdermal forumulations—Alprox-TD(R) for men with erectile dysfunction and Femprox(R) for female sexual arousal disorder. Alprox-TD(R) has been selling in China and in Hong Kong since October 2001 and April 2002, respectively.
| |
| Two Phase III studies have been completed for this product, and the Company is seeking regulatory approval in the U.S., Canada and Europe.
| |
| <ref name=nexm>{{cite web
| |
| | title=NEXM: Dutton Sees Strong Speculative Buy and 12-Month Price Double
| |
| | url=http://www.tradingmarkets.com/.site/news/Stock%20News/722371/
| |
| | author=Fain Hughes
| |
| | date=2007-10-29
| |
| | accessdate=2007-11-01}}</ref>
| |
| | |
| == Other uses==
| |
| Aprostadil is also used in maintaining a [[patent ductus arteriosus]] in the [[fetus]]. This is primarily useful when there is threat of premature closure of the ductus arteriosus.<ref name=dorlands />
| |
| | |
| ==References==
| |
| <references/>
| |
| <br>
| |
| {{Urologicals}}
| |
| {{Prostaglandins}}
| |
| | |
| | |
| [[Category:Prostaglandins]]
| |
| | |
| [[es:Alprostadil]] | |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |